healthcare professional> why cardiolite®> perfusion/function

Myocardial Perfusion and Function assessed by a Gated Cardiolite® Study

In patients with known or suspected CAD .  .  .
The Signs May Be There.

*Based on a prospective study of 5807 patients, designed to determine the incremental prognostic value of SPECT for the prediction of cardiac death and the implications for risk stratification in patients undergoing dual-isotope SPECT with either exercise or pharmacological stress and followed for 642 ± 226 days, with prognostic data available for 5183 patients.5

†Based on a study of 1230 consecutive patients undergoing adenosine stress dual-isotope SPECT and followed up for 27.5 ± 9.1 months.  The evaluation of referral patterns to catheterization was based on 1159 patients, but prognostic data presented here is based on 1079 patients to (1) determine the incremental prognostic value of adenosine stress SPECT; (2) evaluate the ability of SPECT to successfully risk stratify patients in various clinical risk categories; and (3) assess the actual use of this test by healthcare professionals relative to goals 1 and 2 by examining the rates and predictors of referral to catheterization after adenosine stress.7 

Powerful diagnostic and prognostic information helps you optimize your patient management decisions2,3

An MPI with Cardiolite® and gated SPECT combines perfusion and function in a single test2–4 

Perfusion

• Helps establish3
  — Extent of disease (single vessel vs multivessel)3
  — Severity of disease
  — Degree of reversibility

• Predictor of MI and cardiac death3 

The greater the perfusion defect, the greater the risk of MI or cardiac death3

Function

• Helps establish:3,4,7 
  — LVEF and LV function
  — Wall motion
  — Wall thickening

• Predictor of cardiac death3 

The lower the ejection fraction, the greater the risk of cardiac death3

• Cardiolite® with gated SPECT provides incremental prognostic information over perfusion alone in patients with known or suspected coronary artery disease (CAD)8

5-Fold Greater Predictability Over Clinical Testing or Clinical Testing Plus Exercise Treadmill Testing (ETT)9‡§

‡An MPI with Cardiolite® and gated SPECT9

§Based upon a study of 2268 consecutive patients undergoing dual-isotope MPI and followed up for 566 ± 142 days, with 2200 patients available after follow-up; however, the prognostic data was based on a population of 2,113 patients. This study was designed to determine the incremental prognostic value of exercise stress MPI in patients without previously defined CAD, to define the clinical role of the test in risk stratification in this population, and to determine the impact of this test on patient management as measured by post-nuclear testing referral of patients to catheterization and revascularization.9

Rely on the Power of Information Available to You

*Based on a prospective study of 5807 patients, designed to determine the incremental prognostic value of SPECT for the prediction of cardiac death and the implications for risk stratification in patients undergoing dual-isotope SPECT with either exercise or pharmacological stress and followed for 642 ± 226 days, with prognostic data available for 5183 patients.5

||Statistically significant (P<0.05) increase in rate of MI versus cardiac death within scan category5

¶Statistically significant (P<0.001) increase as a scan result5

Adapted from Hachamovitch R, et al.5

It All Adds Up to Information to Help Make Confident Patient Management Decisions

Indications and Usage:   Cardiolite®, Kit for the Preparation of Technetium Tc99m Sestamibi for Injection, is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Cardiolite® evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (eg, exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Important Safety Information: Exercise and pharmacologic stress testing should be performed only under the supervision of a qualified physician. Cardiolite® has been rarely associated with acute severe allergic events of angioedema and urticaria. The most frequently reported adverse events include headache, chest pain/angina, ST segment changes on ECG, nausea, and abnormal taste and smell. Please See Full Prescribing Information